Duchenne Muscular Dystrophy Drug Landscape
As of 2026-11-14, Sarepta’s Elevidys, NS Pharma’s Viltepso, Italfarmaco’s Duvyzat and Catalyst’s Agamree had US approvals, with different eligible populations and regulatory pathways.
Capricor reported on 2026-11-10 that upper-limb decline slowed by 76% after placebo patients switched to deramiocel in the HOPE-3 extension, an open-label cross-period comparison.
Capricor confirmed on 2026-11-10 that the FDA target action date for deramiocel was 2026-11-22; the decision will determine whether cell therapy joins the approved field.
Gene therapy, exon skipping, cell therapy and anti-inflammatory approaches serve different populations. Genotype, age, ambulation and endpoints prevent an across-trial efficacy ranking.
Competitive landscape
| Asset | Company | Mechanism / route | Stage | Indication | Trial identifier | Deal | Latest development | Source |
|---|---|---|---|---|---|---|---|---|
| Elevidys / delandistrogene moxeparvovec | SareptaUS | AAV micro-dystrophin gene therapyIntravenous | US approved; restricted population | Ambulatory DMD, age 4+ | — | — | FDA boxed liver warning and removal of non-ambulatory indication on 2025-11-14 | fda.gov |
| Viltepso / viltolarsen | Nippon Shinyaku / NS PharmaJapan / US | Exon 53-skipping ASOIntravenous | US accelerated approval | DMD amenable to exon 53 skipping | — | — | Clinical benefit requires confirmation; not all-genotype treatment | dailymed.nlm.nih.gov |
| Duvyzat / givinostat | Italfarmaco / ITF TherapeuticsItaly / US | HDAC inhibitorOral | US approved | DMD, age 6+ | — | — | FDA pivotal study: 179 participants; not gene replacement | fda.gov |
| Agamree / vamorolone | Catalyst (North America) / SantheraUS / Switzerland | Modified corticosteroidOral | US approved | DMD, age 2+ | — | — | Catalyst commercializes in North America; corticosteroid precautions apply | catalystpharma.com |
| deramiocel / CAP-1002 | CapricorUS | Allogeneic cardiosphere-derived cellsIntravenous | FDA review | Proposed focus: upper-limb impairment in DMD age >9 | — | — | Target 2026-11-22; OLE cross-period upper-limb decline 1.56 points less (76%); Nippon Shinyaku dispute ongoing | capricor.com |
| z-rostudirsen / DYNE-251 | DyneUS | Muscle-delivered exon 51-skipping therapyIntravenous | FDA Priority Review; confirmatory Phase 3 | DMD amenable to exon 51 skipping | — | — | Company’s July 29 release set target 2027-01-21; not an approval outcome | dynetx.gcs-web.com |
Taiwan and Asia
Nippon Shinyaku’s US subsidiary NS Pharma holds Viltepso for mutations amenable to exon 53 skipping; its accelerated approval requires confirmation of clinical benefit. Capricor’s disclosed dispute with Nippon Shinyaku is a separate rights risk, so historical cooperation is not treated as an uncontested current entitlement. The Japanese program’s eligible genotypes and confirmatory evidence must be assessed separately from broader systemic therapies.